UNION CITY, Calif., April 18, 2017 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2017, ended March 31, 2017. The call will be at 4:15 p.m. ET on Thursday, April 27, 2017. The Company will report financial results for the fourth quarter and fiscal year 2017 after the market closes on Thursday, April 27, 2017.
Participants can dial (844) 855-9498 or (412) 317-5496 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company’s website at www.abaxis.com. A replay of the call is available by visiting www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10105658, through May 4, 2017.
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer of portable blood analysis systems that are used in a broad range of medical specialties in human or veterinary patient care to provide clinicians with rapid blood constituent measurements. Our mission is to improve the efficiency of care delivery to and the quality of life of patients in the medical and veterinary markets. We provide leading edge technology and tools that support best medical practices, enabling physicians and veterinarians to respond to the health needs of their clients at the point of care while operating economical and profitable practices. For more information, visit http://www.abaxis.com.
Contact: | Clint Severson | Lytham Partners, LLC |
Chief Executive Officer | Joe Dorame, Joe Diaz & Robert Blum | |
Abaxis, Inc. | 602-889-9700 | |
510-675-6500 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/abaxis-to-report-fourth-quarter-and-fiscal-year-2017-financial-results-on-thursday-april-27-2017-300441222.html
SOURCE Abaxis, Inc.